🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Fermenta Biotech Limited FERMENTA NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://fermentabiotech.com
Company Profile ↓
₹465.00
+47.05% 1Y
Mkt Cap₹1,333.19 Cr
P/E22.44
P/B3.65
Div. Yield0.66%
52W High₹569.45
52W Low₹279.07
Book Value₹141.68
EPS (TTM)₹20.72

Company Overview

Fermenta Biotech Limited, together with its subsidiaries, engages in the manufacturing and marketing of chemicals, bulk drugs, enzymes, pharmaceutical formulations, and environmental solution products in India, Europe, the United States, and internationally. It operates through Chemicals/Bulk Drug and Property segments. The company offers vitamin D3, including crystalline oil, resin oil, cold water dispersible, and feed grade powder for injectables, soft gel capsules, premixes, food and beverage fortification applications; and vitamin K1, vitamin E50, phenyramidol and silicon dioxide, and fish oil cholesterol. It also provides fortified rice kernel; and Fermase PS 250 and penicillin G acylase used in manufacturing processes of various antibiotics. In addition, the company offers design, engineering, procurement, and construction of wastewater treatment plants, STPs, and ETPs, as well as operation and maintenance services. Further, it is involved in property development business; and renting and selling of properties. The company was formerly known as DIL Limited. Fermenta Biotech Limited was incorporated in 1951 and is based in Thane, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 17.2%, reflecting efficient use of shareholder capital.

Consistent Profit Growth

Net profit has compounded at 47.1% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 12.6% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 22.4, below the sector median of 36.4.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.28.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹525.00 Cr (+12.2% YoY); net profit ₹70.00 Cr.
  • Trailing 12 Months Year-on-year growth — revenue -10.6%, earnings -55.3%.
  • 5-Year Trend Long-term compounding — revenue CAGR 12.6%, profit CAGR 47.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:12.62%
1 Year:-10.60%

Compounded Profit Growth

5 Years:47.14%
1 Year:-55.30%

Stock Price Performance

1 Year:+47.05%
6 Months:+48.76%
3 Months:+16.76%
1 Month:-1.95%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot
52-Week Range 64% of range
₹279.07 ₹569.45
Trend Signals
  • Price vs 50-DMABelow
  • RSI (14)37.14 · Neutral
Price Performance
1M-1.95%
3M+16.76%
6M+48.76%
1Y+47.05%
Valuation vs Sector

P/E of 22.44 is below the sector median of 36.43 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 12.6% over 5 years.
  • Profit CAGR of 47.1% over 5 years.
  • Generates positive free cash flow.

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
22.44
Industry PE
36.43
Forward P/E est.
44.88
PEG Ratio
-
Book Value
₹141.68
Price to Book
3.65
P/S
2.90
EV/EBITDA
19.20
Dividend Yield
0.66%

Growth (CAGR)

Revenue 5Y
12.62%
Profit 5Y
47.14%
Revenue (YoY)
-10.60%
Earnings (YoY)
-55.30%

Profitability & Returns

ROCE
-
ROE
17.24%
ROA
10.80%
Profit Margin
11.68%
Op Margin
10.55%
Gross Margin
60.02%
EPS (Latest Qtr)
₹6.52
EPS (TTM)
₹20.72

Balance Sheet & Liquidity

Debt/Equity
0.28
Quick Ratio
0.97
Current Ratio
1.86
Debt
₹113.33 Cr
Total Assets
₹648.00 Cr
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
65.91%
Chg in Prom Hold
-5.11%
FII / Inst Holding
0.00%
Chg in FII Hold
-0.02%

Financial Snapshot

Enterprise Value
₹1,333.19 Cr
Total Revenue (TTM)
₹510.99 Cr
EBITDA
₹88.32 Cr
Free Cash Flow
₹63.00 Cr
Operating Cash Flow
₹93.00 Cr
Shares Outstanding
₹2.87 Cr
Gross Margin
60.02%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 FERMENTA Fermenta Biotech Limited NSEPHARMA 465.00 22.44 ₹1,333.19 Cr 0.66% - 17.24% 12.62% 47.14%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,745.10 34.62 ₹4.19 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,190.00 83.58 ₹2.44 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,553.80 72.74 ₹1.73 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,117.30 24.90 ₹1.11 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 631.35 164.41 ₹1.09 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,600.00 52.32 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,012.50 99.48 ₹1.09 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,314.00 31.51 ₹1.06 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 105.00 Cr82.00 Cr57.00 Cr99.00 Cr97.00 Cr78.00 Cr95.00 Cr156.00 Cr140.00 Cr136.00 Cr130.00 Cr137.00 Cr122.00 Cr
Operating Expenses 86.00 Cr72.00 Cr71.00 Cr74.00 Cr92.00 Cr77.00 Cr76.00 Cr103.00 Cr103.00 Cr108.00 Cr104.00 Cr112.00 Cr102.00 Cr
Operating Income 13.00 Cr5.00 Cr-20.00 Cr19.00 Cr-1.00 Cr-5.00 Cr13.00 Cr47.00 Cr31.00 Cr22.00 Cr22.00 Cr20.00 Cr15.00 Cr
EBITDA 19.00 Cr11.00 Cr-14.00 Cr25.00 Cr5.00 Cr1.00 Cr19.00 Cr53.00 Cr37.00 Cr28.00 Cr27.00 Cr25.00 Cr20.00 Cr
Interest Expense 6.00 Cr5.00 Cr4.00 Cr5.00 Cr3.00 Cr3.00 Cr4.00 Cr4.00 Cr3.00 Cr3.00 Cr3.00 Cr3.00 Cr3.00 Cr
Pretax Income -1.00 Cr2.00 Cr-29.00 Cr16.00 Cr1.00 Cr-6.00 Cr12.00 Cr45.00 Cr32.00 Cr28.00 Cr24.00 Cr17.00 Cr26.00 Cr
Tax Provision -3.73 Cr0-06.08 Cr8.85 Cr-072.00 L7.20 Cr-1.28 Cr6.44 Cr6.00 Cr5.27 Cr7.54 Cr
Net Income -5.00 Cr2.00 Cr-29.00 Cr10.00 Cr-7.00 Cr-6.00 Cr11.00 Cr38.00 Cr33.00 Cr22.00 Cr18.00 Cr12.00 Cr19.00 Cr
Diluted EPS -1.400.62-9.703.35-2.36-1.983.8712.5411.687.426.144.316.52

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 142.00 Cr155.00 Cr164.00 Cr302.00 Cr403.00 Cr292.00 Cr376.00 Cr397.00 Cr349.00 Cr335.00 Cr468.00 Cr525.00 Cr
Operating Expenses 126.00 Cr134.00 Cr152.00 Cr209.00 Cr248.00 Cr225.00 Cr293.00 Cr335.00 Cr330.00 Cr307.00 Cr352.00 Cr426.00 Cr
Operating Income 7.00 Cr13.00 Cr2.00 Cr81.00 Cr144.00 Cr51.00 Cr63.00 Cr36.00 Cr-10.00 Cr3.00 Cr91.00 Cr78.00 Cr
EBITDA 16.00 Cr21.00 Cr12.00 Cr93.00 Cr156.00 Cr66.00 Cr83.00 Cr62.00 Cr18.00 Cr28.00 Cr115.00 Cr100.00 Cr
Interest Expense 4.00 Cr6.00 Cr10.00 Cr14.00 Cr21.00 Cr20.00 Cr19.00 Cr18.00 Cr21.00 Cr17.00 Cr15.00 Cr12.00 Cr
Pretax Income 3.00 Cr7.00 Cr-6.00 Cr76.00 Cr129.00 Cr43.00 Cr52.00 Cr27.00 Cr-51.00 Cr-10.00 Cr83.00 Cr96.00 Cr
Tax Provision 2.01 Cr4.27 Cr-2.94 Cr21.28 Cr10.32 Cr-15.91 Cr9.36 Cr11.88 Cr-2.04 Cr-14.30 Cr6.64 Cr25.92 Cr
Net Income 1.00 Cr2.00 Cr-9.00 Cr46.00 Cr117.00 Cr60.00 Cr43.00 Cr15.00 Cr-53.00 Cr-24.00 Cr76.00 Cr70.00 Cr
Diluted EPS 0.17-0.41-4.1412.2142.7120.2315.465.25-17.36-7.8426.1224.39

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 262.00 Cr288.00 Cr307.00 Cr385.00 Cr551.00 Cr614.00 Cr687.00 Cr707.00 Cr637.00 Cr548.00 Cr614.00 Cr648.00 Cr
Total Equity 131.00 Cr130.00 Cr144.00 Cr124.00 Cr251.00 Cr309.00 Cr360.00 Cr372.00 Cr315.00 Cr288.00 Cr363.00 Cr406.00 Cr
Total Debt 71.00 Cr89.00 Cr87.00 Cr173.00 Cr209.00 Cr224.00 Cr232.00 Cr239.00 Cr220.00 Cr139.00 Cr115.00 Cr113.00 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 15.00 Cr4.00 Cr2.00 Cr59.00 Cr90.00 Cr34.00 Cr63.00 Cr43.00 Cr116.00 Cr105.00 Cr41.00 Cr93.00 Cr
Investing Cash Flow -18.00 Cr-13.00 Cr7.00 Cr-101.00 Cr-97.00 Cr-44.00 Cr-41.00 Cr-26.00 Cr-55.00 Cr-16.00 Cr-0-43.00 Cr
Financing Cash Flow 1.00 Cr10.00 Cr-12.00 Cr89.00 Cr12.00 Cr-47.00 Cr-1.00 Cr-22.00 Cr-41.00 Cr-91.00 Cr-51.00 Cr-42.00 Cr
Capital Expenditure -35.00 Cr-29.00 Cr-19.00 Cr-17.00 Cr-35.00 Cr-68.00 Cr-56.00 Cr-37.00 Cr-40.00 Cr-19.00 Cr-3.00 Cr-30.00 Cr
Free Cash Flow -20.00 Cr-25.00 Cr-17.00 Cr42.00 Cr55.00 Cr-34.00 Cr7.00 Cr6.00 Cr76.00 Cr86.00 Cr38.00 Cr63.00 Cr
Net Change in Cash -2.00 Cr1.00 Cr-4.00 Cr47.00 Cr6.00 Cr-57.00 Cr21.00 Cr-4.00 Cr19.00 Cr-1.00 Cr-10.00 Cr8.00 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ------------
Operating Margin % 4.9%8.4%1.2%26.8%35.7%17.5%16.8%9.1%-2.9%0.9%19.4%14.9%
Net Margin % 0.7%1.3%-5.5%15.2%29.0%20.5%11.4%3.8%-15.2%-7.2%16.2%13.3%
ROE % 0.8%1.5%-6.2%37.1%46.6%19.4%11.9%4.0%-16.8%-8.3%20.9%17.2%
ROCE % ------------

Shareholding Pattern

Insiders
65.91%
Institutions
0.00%
Public Float
0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for FERMENTA

Google News Mon, 20 Apr 2026

FERMENTA Stock Price and Chart — NSE:FERMENTA - TradingView

<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE1uWEpQcTFwRzlUTTNQQ0xSWm01RjRGM1A0RnQ1UjY5Mkg1TUJ6ZXcxNzkxX2hWU0Nmc215WVpRZ1Uyanhqdk5acFpqeEhOdXlBQ29IMTNFMGRDemNrYWc?oc=5" target="_blank">FERMENTA Stock Price and Chart — NSE:FER…

Google News ue, 16 Jun 2026

Fermenta Biotech Files for Direct NSE Listing to Target 100% Domestic Exchange Access - Sahi

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPano5dmVjVlBsU1JZRFZkeUJFc0pnSXY2VUthQmxsMEhnLXdfNjV3ejRfY3dNYl9wZXROWmxELVltQ0t0THJBVHhfTHB2LUFpZ3plOWVwQUV0RDFpTFduaUVOMU5yOEVQWE1aSHc3YkZ0dGliNlEydk5iSEJTek9wVG90bmV0Zm9aMWVPbV…

Google News Sat, 08 Aug 2026

Fermenta Biotech lists on NSE - BusinessLine

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQZ1hhYzBuTERUUGR5Q0JZZjFFaUZoSHlfRVNKZWQtRTFpSkRCdzZCVElvSko5Y2pWZWM1MnprMS00bEIwQnBycnBlc1llNnhGZml2WUpzTkZsMVQtYWxyVDFUZThGcXU1NnRkZDJfWjZEc0wxRWx1THJFTmJpcy1VeGo4Tm9vVEN5UEp3RU…

Google News ue, 04 Aug 2026

Fermenta Biotech lists equity shares on NSE - Express Pharma

<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTFBVM2NDRmJEUXFaR1lybXlOR2t3QkNmbjhzQzI2bm5TZk9IdUdyREJwOWtiX2NzXy15M2g1Rm5VMVBaS1ZKd3NVMWdtdFF2djh2MEVKTlpob1dmcXpfbktkdTdQVGQ2LUl4VlZNZTBUZmFyY21haEg0dDZNZDNMUQ?oc=5" target="_blan…

Google News hu, 01 Oct 2026

Fermenta Biotech shifts one-to-one investor meeting to Oct 7 - scanx.trade

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPeUFDZ1loMUMyeVZUc0V5eHhLYjRPZ0lRZzJlOGs0UC1sZW1IYWZLWGxETkRHZDFwLVlaU3JXS1FaMEN2MEswMkVMdGVsaHgtLURENkJCRE1aNHR4d2UxaHRxWTBmaFJjdklXZE1XenRoem4zUnNIa1BoUmwwQmdmV0t2RjFBVi02eHBZcm…

Google News Mon, 05 Oct 2026

Fermenta Biotech Share Price near 52-week high after 3.80% - Univest

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxPV3BXV2FYV2t6NzdRMHl2OVAxQVJpSXZ2b0FiaExDaEdaQVBWQVJqVFhrWWJSSUxvMU4zcTRGcTZIakxBSlEyemtoUTV1Y0JtTFFOOUJMb1lWbVZ2RDVzaTF6ZUI3ZDhjV3B0allWU1B3MG8xMDlWTTNobEpTbHhTbjM5azVvUUNWX2x5Zk…

FERMENTA — Frequently Asked Questions

What is the current share price of Fermenta Biotech Limited (FERMENTA)?

As of 2026-10-23 04:58 IST, Fermenta Biotech Limited (FERMENTA) trades at ₹465.00 on NSE. Its 52-week range is ₹279.07 to ₹569.45.

What is the market capitalisation of FERMENTA?

Fermenta Biotech Limited (FERMENTA) has a market capitalisation of ₹1,333.19 Cr on NSE.

What is the P/E ratio of FERMENTA?

FERMENTA trades at a trailing price-to-earnings (P/E) ratio of 22.44. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 3.65.

Does FERMENTA pay a dividend?

Fermenta Biotech Limited (FERMENTA) currently offers a dividend yield of 0.66%.

What is the return on equity (ROE) of FERMENTA?

FERMENTA has a return on equity (ROE) of 17.24%.

Is FERMENTA a good stock to buy?

This page provides a data-driven analysis of Fermenta Biotech Limited (FERMENTA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space